Source comparison
How Many Doses Vial CJC-1295 no DAC & Ipamorelin: Comparison
| Vial Size | Reconstitution Volume | Concentration (Each Peptide) | Dose per Injection | Theoretical Doses | Actual Usable Doses (Standard Syringe) | Actual Usable Doses (LDS Syringe) ||—|—|—|—|—|—|| 5mg / 5mg | 2.0mL | 2.5mg/mL | 0.5mg each | 10 | 8–9 | 9–10
This comparison does not assign a generated winner or score.
- | Vial Size | Reconstitution Volume | Concentration (Each Peptide) | Dose per Injection | Theoretical Doses | Actual Usable Doses (Standard Syringe) | Actual Usable Doses (LDS Syringe) ||—|—|—|—|—|—|| 5mg / 5mg | 2.0mL | 2.5mg/mL | 0.5mg each | 10 | 8–9 | 9–10 || 10mg / 10mg | 2.0mL | 5.0mg/mL | 0.5mg each | 20 | 18–19 | 19–20 || 5mg / 5mg | 1.0mL | 5.0mg/mL | 0.25mg each | 20 | 18–19 | 19–20 || 2mg / 2mg | 2.0mL | 1.0mg/mL | 0.2mg each | 10 | 8–9 | 9–10 |
- Reconstitution volume directly controls peptide concentration, which determines both dose volume and total dose count. Lower reconstitution volumes create higher concentrations, allowing smaller injection volumes but requiring more precise syringe measurements. The 'Actual Usable Doses' columns account for syringe dead space loss. Standard insulin syringes waste 10–15% of solution volume, while low dead space syringes recover most of that loss.